Antidepressant escitalopram performs best at keeping patients free of depression symptoms compared to other common medications, according to a large new analysis published in The Lancet Psychiatry.
The study, which examined nearly 10,000 people prescribed different treatments for up to a year, provides fresh data on long-term outcomes. Medical guidelines commonly recommend selective serotonin reuptake inhibitors, or SSRIs, as the first drug of choice for depression. These medications increase serotonin levels in the brain, a neurotransmitter closely linked to mood regulation and emotional stability.
Patients taking escitalopram were more likely to see their symptoms improve and stay that way. They were also less likely to stop taking their medication compared to those taking fluoxetine, widely known as Prozac. Agomelatine, an atypical antidepressant, and duloxetine, a selective noradrenaline reuptake inhibitor or SNRI, also performed well in the analysis. Other medicines evaluated, including sertraline, were no better.
- Long-Term Efficacy: Escitalopram showed a higher success rate in preventing depressive relapses over a one-year period compared to several alternatives.
The underlying research evaluated previous clinical studies comparing the effectiveness of more than a dozen common antidepressants. Experts note that while the differences found are modest, they offer valuable guidance for clinicians and patients managing long-term care plans. Depression affects roughly one in six people in the UK, making relapse prevention a central focus of public health strategies.
Standard medical guidelines already recommend that patients remain on antidepressants for at least six months after depression symptoms subside, followed by a gradual tapering process. The findings do not imply all patients should immediately switch their prescriptions. Because every medication carries a distinct side-effect profile, treatment choices must remain personalized.
“Nevertheless, our study can help inform the decisions that prescribers and patients make together: if you start an antidepressant, choose one that not only helps you to get well, but also keeps you well.”
Other specialists urged caution when interpreting population-level data for individual clinical care. Dr Sameer Jauhar, an expert at Imperial College London, said that the research cannot predict which specific antidepressant will work best for a given patient. He added that individuals responding well to their current regimen should not interpret the findings as a reason to alter their treatment.
Prof Allan Young from the Royal College of Psychiatrists emphasized that modest differences in long-term outcomes are unlikely to outweigh individual factors. Patient preference, previous treatment response, and side-effect tolerance remain paramount when deciding on an appropriate therapeutic course.
| Medication | Drug Classification | Observed Performance |
|---|---|---|
| Escitalopram | SSRI | Performed best at preventing patients from relapsing |
| Agomelatine / Duloxetine | Atypical / SNRI | Performed well |
| Fluoxetine (Prozac) | SSRI | Ranked just below agomelatine and duloxetine |
| Sertraline | SSRI | No better than other medicines |
Like all pharmacological interventions, escitalopram carries potential adverse effects. Patients may experience sleep disturbances, constipation, and weight gain, although these side effects vary significantly by individual. The NHS notes that if an SSRI proves ineffective or unsuitable, physicians may suggest an alternative class, such as an SNRI. Older tricyclic antidepressants, including amitriptyline, are now prescribed less frequently.
Mental health support extends beyond pharmacotherapy. The mental health charity Mind highlights the necessity of accessible information regarding both potential benefits and adverse effects. Integrating talking therapies and mindfulness practices often supports long-term recovery.
“It’s common for people to need to try more than one medication before they find the right treatment that works for them. And what works may change over time,” the charity said.
Consult a Doctor Before Changing Depression Medication
Patients currently managing depression should never discontinue or switch their medication regimen without direct consultation with a qualified healthcare provider.
References
- The Lancet Psychiatry – Comparative efficacy and acceptability of antidepressants
- BBC News – Health and Medical Reporting
- Yahoo Lifestyle Australia – Clinical Trial Coverage
- National Health Service (NHS) – Antidepressant Guidelines
